Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Breast Neoplasms 1214Neoplasms 1024Carcinoma, Non-Small-Cell Lung 851Prostatic Neoplasms 683Colorectal Neoplasms 608Lung Neoplasms 575Neoplasm Metastasis 431Multiple Myeloma 420Leukemia, Myeloid, Acute 394Pancreatic Neoplasms 371Ovarian Neoplasms 359Melanoma 317Carcinoma, Hepatocellular 284Recurrence 274Squamous Cell Carcinoma of Head and Neck 272Brain Neoplasms 264Glioblastoma 245Head and Neck Neoplasms 241Stomach Neoplasms 236Precursor Cell Lymphoblastic Leukemia-Lymphoma 226Carcinoma, Renal Cell 225Lymphoma 221Triple Negative Breast Neoplasms 216Endometrial Neoplasms 207Hematologic Neoplasms 206Urinary Bladder Neoplasms 195Lymphoma, Non-Hodgkin 194Sarcoma 189Uterine Cervical Neoplasms 187Glioma 187

Interventions

trametinib 1dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Differentiated Thyroid Cancer (DTC) × 90 days × Clear all
NCT04940052 2026-06-04

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

Novartis

Phase 3 Active not recruiting
153 enrolled 15 charts
EndocrineHead & Neck

Differentiated Thyroid Cancer (DTC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡